- Home
- KPTI vs CHRS Comparison
KPTI vs CHRS Comparison
Compare KPTI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | CHRS |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 291.5M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KPTI | CHRS |
|---|---|---|
| Price | $8.54 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $14.67 | $5.51 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | $22.36 | $30.94 |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.65 | $0.72 |
| 52 Week High | $10.99 | $2.62 |
Technical Indicators
Market Signals| Indicator | KPTI | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 58.99 |
| Support Level | $5.84 | $1.55 |
| Resistance Level | $9.00 | $1.87 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | 0.34 | 0.02 |
| Stochastic Oscillator | 90.96 | 96.15 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.